The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.
Icahn School of Medicine at Mount Sinai
Shorts
1:03
Remibrutinib Reduces Daily CSU Disease Activity Within 12 Hours of Treatment
7 months ago
by
Mark Lebwohl, MD
Latest Content
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Conference Preview: 2026 GOLD International COPD Conference
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5